Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Core Insights - Adaptimmune Therapeutics plc is actively participating in significant scientific and medical conferences in November and December 2024 to showcase advancements in cell therapy for solid tumors [1][6]. Conference Participation - At the Society for Immunotherapy of Cancer (SITC) 39th annual meeting, Adaptimmune will present on T-cell therapy for synovial sarcoma and the mechanisms of afami-cel's anti-tumor activity [2]. - The Connective Tissue Oncology Society (CTOS) 2024 annual meeting will feature presentations on the pivotal IGNYTE-ESO trial and the impact of afami-cel on patient health states [3]. - The American Society of Hematology (ASH) 66th Annual Meeting will include a poster presentation on decentralized manufacturing of a T-cell therapy for solid tumors [4]. Company Overview - Adaptimmune is a fully integrated cell therapy company focused on developing personalized medicines targeting difficult-to-treat solid tumor cancers using its engineered T cell receptor (TCR) platform [6].